{"filings":[{"id":110243,"accession_number":"0001193125-26-133331","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.03","2.04","5.02","8.01"],"status":"ready","headline":"IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated","event_type":"other_material","confidence":"high","bullets":["Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.","Chapter 7 trustee to liquidate assets; it is unlikely common stockholders will receive any payment.","All board members (Peter Hirth, Helen Collins, etc.) resigned; CEO Mai-Britt Zocca and CFO Amy Sullivan terminated.","Default triggered on €22.5 million EIB loan; EIB may demand immediate repayment but stay under bankruptcy.","Audit of 2025 financials not completed; company will not file 10-K or any periodic reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110242,"accession_number":"0001193125-26-051790","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"IO Biotech receives Nasdaq MVLS deficiency notice; 180 days to comply","event_type":"regulatory","confidence":"high","bullets":["Notice received Feb 12, 2026; MVLS below $50M for 30 consecutive business days.","Company has until August 11, 2026 to regain compliance.","Stock continues trading on Nasdaq Global Select Market during cure period.","If not cured, Nasdaq will issue delisting notice; company may appeal.","No assurance of regaining compliance with MVLS or other listing rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110241,"accession_number":"0001193125-26-031987","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James","event_type":"other_material","confidence":"high","bullets":["Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.","Board approved restructuring plan; expects $2.4M-$2.6M in one-time charges in Q1 2026.","Chief Medical Officer Qasim Ahmad's employment will end effective Feb 15, 2026.","Company implementing significant global workforce reduction to reduce operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110240,"accession_number":"0001193125-26-017164","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IO Biotech to explore strategic alternatives including merger, sale, or liquidation","event_type":"other_material","confidence":"high","bullets":["Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.","Further reduction-in-force and cost-cutting measures are also under consideration.","No timetable for the process; no assurance any transaction will occur.","IO Biotech (Nasdaq: IOBT) is a clinical-stage cancer vaccine developer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126826,"accession_number":"0001193125-25-327089","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"IO Biotech receives Nasdaq bid price deficiency notice; has until June 16, 2026 to regain compliance","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified IO Biotech on Dec 17, 2025 that bid price < $1.00 for 30 consecutive days.","Company has 180 calendar days, until June 16, 2026, to regain compliance.","To comply, closing bid price must be >= $1.00 for at least 10 consecutive trading days.","If not compliant by June 2026, may apply for a second 180-day period by transferring to Nasdaq Capital Market.","No immediate effect on listing; stock continues trading on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126825,"accession_number":"0001193125-25-291504","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IO Biotech chief accounting officer Burkavage resigns; CFO Sullivan to succeed","event_type":"leadership","confidence":"high","bullets":["Brian Burkavage resigns as SVP and Chief Accounting Officer effective December 12, 2025 to pursue another opportunity; no dispute with company.","CFO Amy Sullivan designated as principal accounting officer upon Burkavage's departure; no new compensatory arrangements entered.","Sullivan's biography previously disclosed in IO Biotech's April 2025 definitive proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126824,"accession_number":"0001193125-25-285282","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"IO Biotech updates investor deck for Jefferies conference; no specific new data in exhibit","event_type":"other_material","confidence":"low","bullets":["Company will present at Jefferies Global Healthcare Conference on November 18, 2025.","Updated investor deck posted to company website on November 18, 2025, and filed with SEC.","Filing exhibit contains only a disclaimer and forward-looking statements; no new financial or operational metrics.","No changes to business strategy, pipeline, or guidance disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126823,"accession_number":"0001193125-25-281657","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q3: Phase 3 melanoma trial narrowly misses PFS endpoint; cash $30.7M, runway to Q1 2026","event_type":"earnings","confidence":"high","bullets":["Phase 3 IOB-013 trial in advanced melanoma showed PFS improvement but narrowly missed statistical significance; FDA meeting in December for new registrational trial design.","Q3 total operating expenses $19.4M, down from $26.5M YoY; R&D expenses $13.7M vs $20.2M prior year.","Cash and equivalents $30.7M as of Sep 30, 2025, down from $60.0M at Dec 31, 2024; expects to fund operations through Q1 2026.","Cash increased $2.5M in Q3 from €12.5M EIB loan drawdown and $6.6M net ATM proceeds.","Pre-clinical data for pipeline candidates IO112 (arginase 1) and IO170 (TGF-β) presented at SITC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143602,"accession_number":"0001193125-25-221704","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"FDA advises IO Biotech not to submit BLA for Cylembio; workforce cut by ~50%","event_type":"regulatory","confidence":"high","bullets":["FDA recommends against BLA submission based on IOB-013 trial data (PFS improved but missed statistical significance).","Company plans new registrational study for first-line advanced melanoma; also engaging European regulators.","Restructuring reduces workforce ~50%; expects $1.0-1.5M severance charges in Q3 2025.","Cash runway extended into Q1 2026 to focus on regulatory path for Cylembio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143601,"accession_number":"0001193125-25-180830","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q2 net loss $26.2M; Ph3 Cylembio trial misses PFS endpoint, plans FDA meeting fall 2025","event_type":"earnings","confidence":"high","bullets":["Phase 3 trial of Cylembio+Keytruda in advanced melanoma showed clinical improvement in PFS but narrowly missed statistical significance.","Company plans to meet with FDA in fall 2025 to discuss data and potential BLA submission for Cylembio.","Net loss of $26.2M for Q2 2025 vs $20.7M in Q2 2024; R&D expenses $16.7M, G&A $6.5M.","Cash and equivalents $28.1M at June 30, 2025; plus €12.5M EIB loan received July 4, funding into Q1 2026.","Upcoming investor conferences: Morgan Stanley (Sept 9) and H.C. Wainwright (Sept 10) with management presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143600,"accession_number":"0001193125-25-177471","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"IO Biotech Phase 3 Cylembio trial misses statistical significance; PFS improved 19.4 vs 11.0 mo","event_type":"other_material","confidence":"high","bullets":["Primary endpoint PFS HR=0.77 (CI 0.58-1.00), p=0.056, missed significance threshold p≤0.045.","Median PFS 19.4 months (Cylembio+pembrolizumab) vs 11.0 months (pembrolizumab alone).","PD-L1 negative subgroup median PFS 16.6 vs 3.0 months (HR 0.54, nominal p=0.006).","OS trend HR=0.79 (CI 0.57-1.10); company expects OS maturity in 6-9 months.","Estimated cash $28.1M as of June 30, plus €12.5M drawn July 4; runway into Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161793,"accession_number":"0001193125-25-151511","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.02","8.01","1.01","9.01"],"status":"ready","headline":"IO Biotech draws €12.5M Tranche B from EIB, issues warrant for 4.22M shares at $1.3159","event_type":"debt","confidence":"high","bullets":["Satisfied conditions to draw €12.5M second tranche (Tranche B) from EIB loan facility of up to €57.5M.","Issued Tranche B warrant to purchase up to 4,221,867 shares of common stock at strike price $1.3159 per share.","Drawdown is expected on or around July 4, 2025.","Warrant terms mirror those disclosed in the December 20, 2024 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161792,"accession_number":"0001193125-25-143658","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"IO Biotech enters CEO severance agreement providing 12-18 months pay and equity vesting","event_type":"other_material","confidence":"high","bullets":["Severance pay: 12 months base salary on qualifying termination; 18 months if termination within 6 months pre- or 12 months post-Change in Control.","Equity awards: 12-month vesting acceleration (standard) or 100% vesting at target (Change in Control scenario).","Pro-rated bonus for termination year plus unpaid prior-year bonus; subject to release and non-compete compliance.","CEO Mai-Britt Zocca: addendum to existing service agreement effective June 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161791,"accession_number":"0001193125-25-137894","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IO Biotech stockholders elect David Smith to board, ratify EY as auditor","event_type":"other_material","confidence":"high","bullets":["David Smith elected as Class I director with 40,444,898 votes for, 3,010,542 withheld, 8,622,498 broker non-votes.","Ratification of EY Godkendt Revisionspartnerselskab as independent auditor: 51,581,966 for, 183,927 against, 312,045 abstain.","Annual Meeting held June 5, 2025; both proposals approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161790,"accession_number":"0001193125-25-134502","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IO Biotech regains Nasdaq minimum bid price compliance after deficiency notice","event_type":"other_material","confidence":"high","bullets":["Received December 26, 2024 notice from Nasdaq for bid price below $1.00 for 30 consecutive days.","On June 3, 2025, Nasdaq Staff confirmed closing bid price at $1.00+ for 10 consecutive business days.","Company has regained compliance with Nasdaq Listing Rule 5450(a)(1); matter is closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161789,"accession_number":"0001193125-25-119406","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IO Biotech Q1 net loss $22.4M; Phase 3 melanoma vaccine readout on track for Q3 2025","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.4M in Q1 2025 vs $19.5M in Q1 2024; R&D expenses rose to $16.4M.","Cash and equivalents $37.1M at March 31, 2025, down from $60.0M at Dec 31, 2024; Q1 cash burn $22.9M.","Drew €10.0M tranche A of EIB loan on May 6; believes conditions met for €12.5M second tranche.","Phase 3 trial primary endpoint (PFS) readout on track for Q3 2025; BLA submission planned in 2025.","Enrollment completed in Phase 2 basket trial (IOB-032) for SCCHN/melanoma; initial data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161788,"accession_number":"0001193125-25-107501","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["3.02","8.01","1.01","9.01"],"status":"ready","headline":"IO Biotech issues warrant to EIB for up to 5.6M shares at $0.8891; €10M draw expected May 6","event_type":"other_material","confidence":"high","bullets":["Issued Tranche A Warrant to EIB to purchase up to 5,623,664 shares of common stock at $0.8891 per share.","Warrant issued in connection with €10M draw under previously announced EIB loan facility of up to €57.5M.","Drawdown of €10M Tranche A loan expected on or around May 6, 2025.","Warrant issued in private placement exempt from registration under Section 4(a)(2) of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179885,"accession_number":"0001193125-25-045673","cik":1865494,"company_name":"IO Biotech, Inc.","ticker":"IOBTQ","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.","Cash and equivalents ~$60M as of Dec 31, 2024; secured up to €57.5M EIB debt, extending runway into Q2 2026.","Phase 2 basket trial (resectable melanoma/SCCHN) enrollment completed at 95 patients; initial data expected H2 2025.","Phase 2 IOB-022 met primary endpoint ORR in SCCHN; promising PFS in SCCHN and NSCLC; longer-term data H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}